Cell and Gene Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Oncology, Rare Diseases, Neurology, Regenerative Medicine, Clinical Trials), By Application (Novartis (Switzerland), Gilead Sciences (USA), Roche (Switzerland), Pfizer (USA), Merck & Co. (USA), Bristol - Myers Squibb (USA), Johnson & Johnson (USA), Celgene (now part of Bristol - Myers Squibb, USA), Bluebird Bio (USA), Kite Pharma (now part of Gilead Sciences, USA)), Regional Insights and Forecast From 2026 To 2035

Cell and Gene Therapy Market Overview

The global cell and gene therapy market size is predicted to reach USD 390826.76 Million by 2035 from USD 60208.21 Million in 2026, registering a CAGR of 23.1% during the forecast from 2026 to 2035.

The Cell and Gene Therapy Market represents one of the fastest-evolving segments of advanced biopharmaceutical innovation, supported by increasing regulatory approvals, expanding clinical pipelines, and growing adoption of precision medicine. As of 2025, more than 4,500 cell and gene therapy clinical trials have been registered globally, with over 2,000 actively recruiting patients. More than 30 approved gene and cell therapy products are commercially available across major healthcare markets. Oncology accounts for nearly 48% of ongoing development programs, while rare diseases represent approximately 27%. Viral vectors contribute over 65% of gene delivery platforms, and autologous therapies constitute nearly 58% of approved cell-based treatments worldwide.

The United States remains the largest contributor to the Cell and Gene Therapy Market, supported by a strong biotechnology ecosystem and extensive clinical research infrastructure. More than 1,700 active cell and gene therapy clinical trials are being conducted in the country as of 2025. The U.S. Food and Drug Administration has approved over 20 cell and gene therapy products, accounting for nearly 60% of global commercialized therapies. More than 1,200 biotechnology companies in the United States are engaged in advanced therapy development. Approximately 72% of domestic gene therapy programs target oncology and rare diseases. Manufacturing capacity utilization exceeds 80% in several major bioprocessing hubs, supporting increased commercialization activities.

Key Findings

• Key Market Driver: More than 68% of advanced therapy pipelines focus on unmet medical needs, while 74% of rare disease programs target conditions lacking approved treatments and 63% of ongoing studies report positive efficacy endpoints.
• Major Market Restraint: Approximately 57% of developers identify manufacturing complexity as a barrier, while 49% report supply-chain limitations, 46% face scalability concerns, and 41% encounter regulatory compliance challenges.
• Emerging Trends: Nearly 62% of new development programs incorporate gene-editing technologies, 54% utilize next-generation viral vectors, 47% adopt automation platforms, and 44% focus on allogeneic therapy approaches.
• Regional Leadership: North America accounts for approximately 46% of global clinical activity, Europe contributes 27%, Asia-Pacific represents 22%, while the remaining 5% is distributed across other regions.
• Competitive Landscape: The top 10 companies collectively control approximately 61% of approved therapy portfolios, while 39% remains distributed among emerging biotechnology firms and specialized therapy developers.
• Market Segmentation: Cell therapy represents approximately 58% of commercial activity, gene therapy accounts for 42%, oncology contributes 48% of applications, and rare diseases comprise 27%.
• Recent Development: Around 66% of recent approvals involve genetic modification technologies, 53% utilize viral vector platforms, 38% focus on hematological conditions, and 31% target rare genetic disorders.

Cell and Gene Therapy Market Latest Trends

The Cell and Gene Therapy Market is witnessing significant transformation driven by technological advances and broader therapeutic applications. Gene-editing platforms such as CRISPR are incorporated into approximately 62% of newly initiated gene therapy programs. More than 780 gene therapy candidates are currently under clinical evaluation worldwide. Cell therapy programs exceed 1,900 active studies, reflecting increasing research intensity. Allogeneic cell therapies are gaining attention due to manufacturing efficiency, representing nearly 43% of newly launched cell therapy trials in 2025. Automation adoption within manufacturing facilities has increased by 37% since 2022, improving production consistency and reducing contamination risks. Viral vector production capacity expanded by approximately 29% during the last three years to address growing clinical demand.

Artificial intelligence is increasingly used in therapy design, with 34% of advanced therapy developers employing machine-learning tools during target identification and patient selection processes. Oncology continues to dominate development activity, accounting for 48% of total clinical programs. Hematologic cancers represent 31% of oncology-focused studies. Regulatory agencies have accelerated review mechanisms for rare disease therapies, leading to increased development activity. Nearly 58% of approved gene therapies target inherited disorders. In vivo gene therapies account for approximately 55% of ongoing gene-based clinical investigations, while ex vivo approaches represent 45%, demonstrating balanced innovation across delivery methodologies.

Cell and Gene Therapy Market Dynamics

DRIVER

"Rising demand for personalized and precision medicine"

The growing emphasis on personalized healthcare is a major factor driving the Cell and Gene Therapy Market. More than 300 million people globally are affected by rare diseases, and approximately 72% of these conditions have a genetic origin. Gene therapies provide targeted interventions at the molecular level, increasing treatment effectiveness. More than 65% of advanced therapy clinical programs focus on patient-specific treatment strategies. Precision medicine initiatives have expanded across over 80 countries, supporting advanced therapy development. Clinical data indicate response rates exceeding 70% in several approved cell therapy indications. Furthermore, over 48% of ongoing advanced therapy trials target oncology, where personalized approaches are particularly valuable. These factors continue to increase adoption rates and attract significant research activity.

RESTRAINT

"Complex manufacturing and supply chain requirements"

Manufacturing remains a major restraint within the Cell and Gene Therapy Market. Approximately 57% of therapy developers cite manufacturing complexity as a primary operational challenge. Autologous therapies require individualized processing, increasing logistical burdens and extending production timelines. More than 45% of manufacturing facilities report capacity limitations. Viral vector shortages affect approximately 39% of developers during clinical production stages. Quality control procedures involve over 100 critical analytical tests for many advanced therapies. Cold-chain transportation requirements often demand storage temperatures below minus 150 degrees Celsius. Regulatory documentation volumes have increased by approximately 33% over the past five years, adding operational complexity. These factors collectively limit scalability and delay broader commercialization efforts.

OPPORTUNITY

"Expansion of gene-editing and regenerative medicine applications"

The integration of gene-editing technologies presents substantial opportunities for market expansion. CRISPR-based programs account for approximately 62% of emerging gene-editing projects. More than 1,000 inherited genetic disorders have identifiable molecular targets suitable for advanced therapy intervention. Regenerative medicine applications are increasing rapidly, with over 600 active clinical studies focused on tissue repair and organ regeneration. Stem-cell-based therapies represent nearly 35% of regenerative medicine investigations. Neurological disorders account for approximately 14% of newly initiated gene therapy programs. More than 90% of rare diseases currently lack approved curative treatments, creating significant therapeutic opportunities. Increasing investment in manufacturing automation also supports commercialization potential by improving efficiency and production consistency.

CHALLENGE

"Regulatory and long-term safety monitoring requirements"

Long-term patient monitoring remains a critical challenge within the Cell and Gene Therapy Market. Regulatory authorities frequently require follow-up periods extending to 15 years for certain gene therapies. Approximately 44% of developers identify post-treatment monitoring obligations as a major challenge. Safety assessments involve extensive genomic and immunological evaluations. More than 28% of clinical programs experience delays related to regulatory review processes. Patient recruitment challenges affect approximately 36% of rare disease studies due to limited population sizes. Data management requirements continue to increase, with advanced therapy trials generating up to 10 times more biological datasets than conventional pharmaceutical studies. These complexities create operational and compliance burdens across the development lifecycle.

Cell and Gene Therapy Market Segmentation

The Cell and Gene Therapy Market is segmented by type and application, reflecting diverse treatment approaches and therapeutic targets. Cell therapy accounts for approximately 58% of commercial activity due to established adoption in oncology and regenerative medicine. Gene therapy contributes 42%, supported by expanding approvals for inherited disorders. Oncology remains the largest application segment with 48% market participation, followed by rare diseases at 27%. Neurology contributes 14%, regenerative medicine represents 8%, and clinical trial applications account for 3%. More than 4,500 active clinical studies globally support ongoing segment expansion. Technological innovations in gene editing, viral vectors, and cell engineering continue influencing segment development patterns.

By Type

Based on Type, the global market can be categorized into Cell Therapy (Autologous, Allogeneic), Gene Therapy (Ex Vivo, In Vivo).

• Cell Therapy (Autologous, Allogeneic): Cell therapy represents approximately 58% of the Cell and Gene Therapy Market. Autologous therapies account for nearly 61% of cell therapy activity because they utilize patient-derived cells, reducing immune rejection risks. More than 20 approved cell therapy products are available globally. CAR-T therapies constitute approximately 46% of commercial cell therapy utilization. Allogeneic therapies represent 39% of cell therapy activity and are expanding due to scalable manufacturing capabilities. Over 800 active cell therapy clinical trials are focused on oncology indications. Regenerative medicine contributes approximately 24% of cell therapy development programs. Manufacturing automation adoption has increased by 37%, improving consistency and supporting broader therapeutic deployment.

• Gene Therapy (Ex Vivo, In Vivo): Gene therapy accounts for approximately 42% of the Cell and Gene Therapy Market. In vivo gene therapy represents 55% of ongoing gene-based clinical investigations and involves direct delivery of genetic material into patients. Ex vivo approaches contribute 45% and involve genetic modification outside the body before reinfusion. More than 780 gene therapy candidates are under clinical evaluation globally. Viral vectors are used in approximately 65% of gene therapy programs. Rare disease applications account for nearly 47% of gene therapy development activities. Oncology contributes approximately 32% of ongoing gene therapy studies. Gene-editing technologies are incorporated into 62% of newly launched gene therapy research initiatives.

By Application

• Oncology: Oncology is the largest application segment, accounting for approximately 48% of the Cell and Gene Therapy Market. More than 2,100 clinical studies focus on cancer treatment applications. Hematologic malignancies represent approximately 31% of oncology-based advanced therapy programs. CAR-T therapies demonstrate response rates exceeding 70% in several blood cancer indications. More than 400 oncology-focused gene therapy programs are under development globally. Precision medicine adoption has increased patient stratification efficiency by approximately 35%. The increasing prevalence of cancer, exceeding 20 million annual new cases worldwide, continues driving demand for innovative therapeutic solutions within this segment.

• Rare Diseases: Rare diseases account for approximately 27% of the Cell and Gene Therapy Market. More than 300 million individuals worldwide are affected by rare conditions, and nearly 72% possess genetic origins. Over 1,000 rare diseases have identifiable molecular targets suitable for gene therapy intervention. Approximately 58% of approved gene therapies focus on inherited disorders. Regulatory incentives support development activities across multiple jurisdictions. More than 500 active clinical trials target rare disease indications. Patient populations remain limited, but clinical efficacy rates often exceed 60% in targeted genetic disorders, encouraging continued investment and innovation throughout this application segment.

• Neurology: Neurology represents approximately 14% of the Cell and Gene Therapy Market. More than 120 gene and cell therapy candidates are being evaluated for neurological disorders. Parkinson’s disease, Huntington’s disease, spinal muscular atrophy, and amyotrophic lateral sclerosis remain major therapeutic targets. Approximately 18% of newly initiated gene therapy programs address central nervous system conditions. Advanced viral vectors improve blood-brain barrier penetration efficiency. More than 40 active neurological gene therapy trials entered mid-stage development during the last three years. Genetic neurological disorders affect millions globally, creating substantial demand for disease-modifying treatments and supporting future segment expansion.

• Regenerative Medicine: Regenerative medicine contributes approximately 8% of the Cell and Gene Therapy Market. More than 600 clinical studies investigate tissue regeneration, organ repair, and stem-cell-based therapeutic approaches. Stem-cell therapies account for approximately 35% of regenerative medicine development activities. Orthopedic applications represent 28% of regenerative medicine trials. Cardiovascular regeneration programs contribute approximately 19%. Cell-based regenerative therapies demonstrate increasing effectiveness in repairing damaged tissues. More than 150 institutions worldwide actively conduct regenerative medicine research. Advances in biomaterials, cell engineering, and tissue scaffolding continue enhancing treatment outcomes and expanding commercial opportunities within this segment.

• Clinical Trials: Clinical trial applications account for approximately 3% of the Cell and Gene Therapy Market but remain essential for innovation. More than 4,500 active advanced therapy studies are underway globally. Phase I studies represent approximately 46% of ongoing trials, while Phase II accounts for 34% and Phase III contributes 20%. Oncology-focused clinical trials represent 48% of total activity. Approximately 62% of emerging programs utilize gene-editing technologies. Trial enrollment exceeds 250,000 participants globally across advanced therapy studies. Increased regulatory support and improved trial infrastructure continue accelerating development timelines and supporting future product commercialization.

Cell and Gene Therapy Market Regional Outlook

• North America

North America accounts for approximately 46% of the Cell and Gene Therapy Market. The region hosts more than 2,000 active clinical trials and over 900 specialized biotechnology companies involved in advanced therapy development. The United States contributes nearly 90% of regional activity. More than 20 approved cell and gene therapies are commercially available across North America. Oncology programs represent approximately 49% of ongoing studies. Manufacturing infrastructure remains highly developed, with more than 150 dedicated advanced therapy production facilities operating across the region. Viral vector manufacturing capacity utilization exceeds 80% in several biotechnology clusters. More than 60% of North American developers incorporate automated production technologies.

Regulatory support continues strengthening regional leadership. Expedited review pathways are utilized by approximately 45% of advanced therapy submissions. Rare disease programs account for nearly 28% of development activity. Academic institutions contribute significantly, with over 300 specialized research centers conducting cell and gene therapy investigations. Strategic collaborations between biotechnology companies and healthcare providers continue accelerating clinical adoption and commercialization efforts throughout North America.

• Europe

Europe represents approximately 27% of the Cell and Gene Therapy Market. More than 1,100 active clinical trials are being conducted across the region. Germany, France, the United Kingdom, Italy, and Spain collectively account for over 70% of European development activity. Rare disease programs contribute approximately 31% of regional research initiatives. The region hosts more than 250 advanced therapy manufacturing facilities and research centers. Academic participation remains substantial, with over 180 institutions actively involved in cell and gene therapy development. Oncology applications account for approximately 46% of ongoing studies.

Regulatory frameworks support innovation through specialized pathways for advanced therapy medicinal products. More than 15 commercially available advanced therapies are approved across European markets. Gene therapy programs account for approximately 44% of regional development activity, while cell therapies contribute 56%. Manufacturing automation adoption has increased by approximately 32% since 2022. Cross-border research collaborations and public-private partnerships continue strengthening Europe's position as a major contributor to global cell and gene therapy advancement.

• Asia-Pacific

Asia-Pacific accounts for approximately 22% of the Cell and Gene Therapy Market and represents the fastest-expanding clinical research region. More than 900 active clinical studies are underway across China, Japan, South Korea, Australia, and India. China contributes approximately 52% of regional clinical activity. The region hosts more than 400 specialized biotechnology organizations focused on advanced therapies. Oncology applications represent approximately 51% of regional development programs. Gene-editing technologies are incorporated into nearly 58% of newly initiated studies.

Government support initiatives have increased advanced therapy research funding programs across several countries. More than 120 manufacturing facilities support commercial and clinical production requirements. Japan maintains a strong regulatory framework for regenerative medicine products, while China leads in clinical trial volume. Rare disease studies account for approximately 24% of regional activity. Increasing healthcare infrastructure development and biotechnology investment continue enhancing Asia-Pacific's influence within the global Cell and Gene Therapy Market.

• Middle East & Africa

The Middle East & Africa region accounts for approximately 5% of the Cell and Gene Therapy Market. More than 150 advanced therapy clinical studies are underway across key countries including Saudi Arabia, the United Arab Emirates, South Africa, and Israel. Oncology applications represent approximately 47% of regional research activity. Healthcare modernization initiatives have increased biotechnology infrastructure development. More than 40 specialized research institutions participate in advanced therapy programs. Gene therapy studies account for approximately 43% of regional development activity. Rare disease investigations contribute nearly 22%.

Government-sponsored precision medicine programs continue supporting market expansion. Clinical trial participation has increased by approximately 26% since 2022. Manufacturing capabilities remain limited compared to other regions, although investments in biotechnology facilities continue increasing. International collaborations support knowledge transfer and technology adoption. Improved healthcare access and growing awareness of genetic disorders are expected to strengthen regional participation in advanced therapy research and commercialization activities.

List of Top Cell and Gene Therapy Companies

• Novartis (Switzerland)
• Gilead Sciences (USA)
• Roche (Switzerland)
• Pfizer (USA)
• Merck & Co. (USA)
• Bristol - Myers Squibb (USA)
• Johnson & Johnson (USA)
• Celgene (now part of Bristol - Myers Squibb, USA)
• Bluebird Bio (USA)
• Kite Pharma (now part of Gilead Sciences, USA)

Top 2 Companies with Highest Market Share

• Gilead Sciences (through Kite Pharma): Holds approximately 18% share of the commercial CAR-T therapy segment, with treatment availability across more than 30 countries and thousands of treated patients globally.
• Novartis: Accounts for approximately 15% share of the advanced cell and gene therapy landscape, supported by broad CAR-T adoption, multiple approved indications, and extensive global treatment center networks.

Investment Analysis and Opportunities

Investment activity within the Cell and Gene Therapy Market remains focused on manufacturing expansion, vector production, automation technologies, and gene-editing platforms. More than 500 dedicated manufacturing projects have been announced globally since 2020. Approximately 41% of investment initiatives target viral vector production capacity. Manufacturing automation projects account for nearly 29% of facility upgrades. Over 4,500 active clinical trials create substantial opportunities for contract development and manufacturing organizations. More than 62% of emerging therapy programs incorporate advanced genetic engineering technologies, increasing demand for specialized production capabilities. Rare diseases represent a significant opportunity, with over 90% of known rare conditions lacking approved curative treatments.

Asia-Pacific attracts increasing investment due to expanding clinical trial infrastructure and growing biotechnology ecosystems. More than 120 new advanced therapy facilities have been established across the region during recent years. Artificial intelligence integration in therapy development has increased by approximately 34%, creating opportunities for technology providers. Personalized medicine expansion continues generating demand for advanced therapy manufacturing services. More than 300 million people worldwide affected by rare diseases remain a major target population. Strategic partnerships between biotechnology firms, research institutions, and healthcare providers continue supporting innovation and accelerating commercialization pathways.

New Product Development

Innovation remains a defining characteristic of the Cell and Gene Therapy Market. More than 780 gene therapy candidates and 1,900 cell therapy programs are currently progressing through clinical development. Approximately 62% of new projects incorporate gene-editing technologies, including CRISPR-based approaches. Next-generation viral vectors have improved gene delivery efficiency by over 30% compared with earlier platforms. More than 54% of newly launched gene therapy studies utilize optimized vector designs. In vivo therapies account for 55% of emerging gene therapy products, reflecting increased interest in direct genetic delivery.

Allogeneic cell therapies represent approximately 43% of newly initiated cell therapy programs due to their scalability advantages. More than 200 advanced therapy candidates entered clinical testing during the last two years. Oncology remains the leading innovation area, accounting for approximately 48% of development activity. Digital manufacturing technologies are increasingly incorporated into production systems. Automation adoption has increased by 37%, improving consistency and reducing processing variability. Researchers are also developing multi-gene editing approaches capable of addressing complex disorders. These innovations continue expanding therapeutic possibilities across oncology, neurology, regenerative medicine, and rare disease treatment areas.

Five Recent Developments (2023-2025)

• January 2023: Bluebird Bio expanded commercialization efforts for gene therapies targeting genetic blood disorders, with clinical data demonstrating treatment responses in more than 80% of evaluated patients.
• June 2023: Bristol Myers Squibb reported expanded clinical evidence for CAR-T therapies, involving patient datasets exceeding 1,000 treated individuals across multiple oncology indications.
• March 2024: Novartis advanced manufacturing optimization initiatives, increasing production efficiency by approximately 25% through automation and digital process controls.
• August 2024: Gilead Sciences and Kite Pharma expanded treatment center networks, increasing certified therapy administration locations by more than 20% across major healthcare markets.
• February 2025: Pfizer advanced multiple gene therapy programs into later-stage clinical evaluation, with patient enrollment exceeding 500 participants across targeted rare disease studies.

Report Coverage of Cell and Gene Therapy Market

This report provides comprehensive coverage of the Cell and Gene Therapy Market across major technologies, therapeutic applications, regional markets, and competitive developments. The analysis evaluates more than 4,500 active clinical trials, over 30 approved commercial therapies, and more than 2,000 actively recruiting studies. Market assessment includes cell therapy and gene therapy segments, covering autologous, allogeneic, ex vivo, and in vivo platforms. The report examines key applications including oncology, rare diseases, neurology, regenerative medicine, and clinical research activities. Oncology accounts for approximately 48% of development programs, while rare diseases contribute 27%. More than 300 million individuals affected by rare disorders are considered within demand analysis.

Regional evaluation covers North America, Europe, Asia-Pacific, and Middle East & Africa. North America maintains approximately 46% market share, Europe 27%, Asia-Pacific 22%, and Middle East & Africa 5%. The study assesses manufacturing infrastructure, regulatory frameworks, and clinical trial distribution patterns. Competitive analysis includes leading biotechnology and pharmaceutical companies involved in advanced therapy development. More than 1,200 biotechnology organizations worldwide participate in cell and gene therapy research. The report also reviews investment trends, manufacturing advancements, product innovation, automation adoption, gene-editing integration, and strategic expansion initiatives shaping the future direction of the Cell and Gene Therapy Market.